Pathological hotspots and reflections on clinical diagnosis and treatment of breast cancer
10.13315/j.cnki.cjcep.2025.11.001
- VernacularTitle:乳腺癌临床诊疗的病理热点与思考
- Author:
Yan DING
1
;
Yueping LIU
1
Author Information
1. 河北医科大学第四医院病理科,石家庄 050011
- Publication Type:Journal Article
- Keywords:
breast cancer;
triple negative breast cancer;
HER2-low expression;
immunohistochemistry;
molecular de-tection
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(11):1401-1404
- CountryChina
- Language:Chinese
-
Abstract:
With the in-depth promotion of precision medicine for breast cancer,pathological diagnosis has changed from traditional histological classification to a multidimensional system integrating morphology,immunohistochemistry and molecular target detection,and becoming a pivotal component in clinical treatment decision-making.Currently,the pathological diagnosis of breast cancer necessitates continuous optimization,including standardizing the interpretation of HER2-low expression,promoting the upfront detection for key targets,refining the structure of pathological reports,and further enhancing collaboration with clinical teams.These efforts aim to better meet the demands of precision treatment and provide patients with superior diagnostic support.Based on the clinical research progress and guideline consensus in recent years,this paper delves into the critical pathological hotspots in the clinical diagnosis and treatment of breast cancer,aiming to facilitate the implementation of standardized pathological diagnosis within the precision treatment framework.
